Leqvio Side Effects: What Real Patients Report

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy, not a monoclonal antibody like the PCSK9 inhibitors alirocumab (Praluent) or evolocumab (Repatha), and not a statin. It is FDA-approved for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional LDL cholesterol lowering, given as a 284 mg subcutaneous injection at month 0, month 3, and then every 6 months by a healthcare provider, not self-administered.

The direct answer: across Reddit threads, Drugs.com reviews, and other patient forums, the side effect patients describe most often is a mild, self-limited injection-site reaction (redness, soreness, or a small firm area lasting one to three days), followed by transient fatigue or body aches in the days after an injection. This pattern is broadly consistent with the adverse reaction categories listed in Leqvio's FDA-approved prescribing information, but the total pool of detailed online reports is small (likely well under 1,000 across all platforms), self-selected toward people who had a noticeable reaction, and not a substitute for the controlled adverse-event tracking done in the inclisiran trials. Treat forum patterns as hypothesis-generating, not as an incidence rate.

This page is a source audit: it separates what patient forums say from what regulatory and trial documentation actually supports, and it flags where a precise-sounding number needs verification before you rely on it.

Why online reviews and trial data will not match

Patient-reported data on Leqvio comes from a small, self-selected group. Reddit communities such as r/cholesterol and r/CardiovascularHealth carry scattered anecdotes. Drugs.com hosts a review count in the low hundreds. Other forums are sparser still. People who feel unusually tired or notice a skin reaction after an injection are more likely to post than people who felt nothing, so forum content will always skew toward complaints relative to a systematically tracked trial population.

That does not make forum reports worthless. They can surface symptom clusters, timing patterns, and quality-of-life effects that a structured adverse-event case report form might miss or bundle into a broader category. But they cannot establish how common a side effect truly is. A thread with dozens of replies describing the same symptom is a signal worth asking a clinician about, not a rate.

Injection-site reactions: the most discussed complaint

Injection-site reaction is the single most frequently mentioned side effect across patient platforms, and it is also the adverse reaction most consistently listed in Leqvio's FDA-approved prescribing information as occurring more often with inclisiran than with placebo. Forum descriptions generally cluster around three things: redness lasting roughly 12 to 48 hours, a small firm or mildly swollen area under the skin, and soreness comparable to a flu shot. Most users who mention this describe it as a minor, short-lived annoyance rather than a reason to stop treatment.

Several Reddit users contrast this twice-yearly injection-site discomfort with daily statin-related muscle symptoms they experienced previously. That comparison is plausible in direction (an injection reaction lasting a day or two, twice a year, is a different burden than a daily symptom), but head-to-head tolerability comparisons between inclisiran and statins have not been directly studied in a randomized trial designed for that question, and individual statin tolerability varies widely. A clinician can help weigh this trade-off for a specific patient history.

Fatigue and general malaise

After injection-site reactions, fatigue is the complaint that recurs most often in forum posts. The pattern described online is fairly consistent: low energy or mild body aches beginning within about 24 hours of the injection, resolving within one to three days, sometimes compared to the malaise after a vaccine.

This is a case where forum reports and labeled trial data may not line up cleanly. Fatigue is not consistently singled out in the adverse reaction tables that inform prescribing information at a rate clearly above placebo. There are several possible explanations, and none is confirmed: the symptom may be real but too mild or too short-lived for trial participants to report as a discrete adverse event, people posting online may be more attentive to or vocal about somatic symptoms, or some of what is reported could reflect a nocebo effect (see below). Readers should not treat "fatigue" as an established Leqvio side effect at a specific rate; it is a plausible, patient-reported pattern that has not been cleanly isolated in controlled data available to this review.

Muscle and joint symptoms, and the nocebo question

A smaller recurring thread describes muscle aches or joint stiffness, usually in the first week after an injection. This deserves a specific caveat: many people starting Leqvio have a history of statin-associated muscle symptoms and may already be watching closely for any muscle-related sensation. Randomized, blinded statin research has repeatedly shown that muscle symptom reporting can be similar between drug and placebo arms once patients cannot tell which they are taking, a phenomenon generally described as a nocebo effect. Whether the same dynamic explains some of the muscle or joint complaints attributed to Leqvio online has not been specifically tested, and it should be stated as a plausible contributor rather than a proven explanation.

Joint pain (arthralgia) does appear as a labeled adverse reaction category for inclisiran, but published analyses of the pivotal ORION-10 and ORION-11 trials found rates in the inclisiran and placebo arms that were close enough to each other that a specific drug effect could not be confidently distinguished from background rates in a population with cardiovascular disease and metabolic comorbidities. Exact percentages from those trials are not reproduced here because the underlying citation could not be independently verified for this draft; anyone relying on a specific percentage should check it against the current FDA label or the original trial publication before using it clinically or in patient materials.

Upper respiratory symptoms

A subset of forum posts mentions cold-like symptoms, congestion, or a mild cough in the week following an injection. Bronchitis appears among the adverse reactions listed in Leqvio's prescribing information at a rate above placebo. Inclisiran works by silencing PCSK9 messenger RNA inside liver cells after being delivered there by a GalNAc conjugate designed to limit exposure elsewhere in the body; whether this mechanism has any plausible link to mild respiratory symptoms is not established, and no mechanistic pathway connecting the two has been confirmed in the material available for this review. Reported respiratory complaints online are generally described as mild and self-resolving; no severe respiratory events attributed to Leqvio were found in the forum material reviewed for this page.

Reports of efficacy and satisfaction with dosing

Not every forum post is about a side effect. A meaningful share of posts describe substantial LDL cholesterol reductions and satisfaction with only needing two provider-administered injections a year instead of a daily pill. Self-reported LDL drops mentioned online (roughly from the 130 to 180 mg/dL range down to 50 to 80 mg/dL after two or three injections) are broadly consistent with the magnitude of LDL-C lowering (roughly 50%) that has been reported for twice-yearly inclisiran dosing in trial settings, though individual forum numbers are unverified self-reports, not clinical measurements collected under trial conditions.

The dosing schedule itself, rather than efficacy, is the feature patients describe most consistently as a relief, particularly those who found daily statin dosing difficult to sustain or tolerate.

Cost and access complaints are not tolerability data

A large share of negative Leqvio reviews on patient platforms concerns cost and insurance approval, not the drug's physical side effects. Leqvio has carried a list price in the low thousands of dollars per injection; exact current pricing should be verified directly with Novartis or a pharmacy, since list prices change and this figure is time-sensitive. Reported step-therapy requirements (documented statin intolerance or failure of other oral lipid-lowering agents) can delay approval by months for some patients, and that frustration sometimes shows up as a one-star drug review that reflects billing, not the medication's effects. For Medicare patients, Leqvio is typically billed under Part B rather than Part D because it is administered in a provider's office; the CMS coverage framework generally covers FDA-approved indications, but local coverage determinations and reimbursement logistics vary and can independently drive negative online sentiment. A one-star review driven by an unexpected bill tells you nothing about whether the drug was well tolerated.

Reading online reviews without over- or under-weighting them

Research on online drug reviews generally finds that dissatisfied patients post more often than satisfied ones, so the absence of glowing reviews is not evidence that a drug is poorly tolerated. Conversely, a handful of vivid, specific complaints in a thread should not be read as an established side-effect rate. Both distortions are common, and this page is written specifically to counter them for Leqvio.

When to contact your prescribing clinician

Most reported reactions are mild and short-lived, but the following should prompt a call rather than a wait-and-see approach: an injection-site reaction that worsens after 72 hours or shows signs of infection (increasing warmth, pus, spreading redness); muscle weakness rather than ordinary soreness; facial swelling, difficulty breathing, or a rash spreading beyond the injection site; or any symptom that interferes with daily activities for more than about five days after an injection. This is general safety guidance, not individualized medical advice, and does not replace a conversation with the clinician managing your treatment.

What is established, what is plausible, and what is not established

• Established: Leqvio is FDA-approved for HeFH and ASCVD patients needing additional LDL-C lowering, dosed twice yearly after an initial loading dose. Injection-site reactions are a labeled adverse reaction more common with inclisiran than placebo. Serious statin-associated muscle symptoms are a recognized, separate phenomenon that some Leqvio patients have a history of.
• Plausible but unproven from the material reviewed here: that patient-reported fatigue after injections represents a true drug effect at a rate meaningfully above what trial adverse-event coding captured; that some muscle or joint complaints reflect a nocebo effect carried over from prior statin intolerance; that mild post-injection respiratory symptoms have any mechanistic link to the siRNA delivery platform.
• Not established: precise percentage comparisons between inclisiran and placebo for arthralgia, fatigue, or bronchitis could not be independently verified for this draft and are not reproduced as exact figures; a direct, head-to-head tolerability comparison between inclisiran and statins; and long-term (multi-year) safety and cardiovascular outcome data beyond what has been published from the initial trial program.

Evidence-review framework: reported experience versus controlled evidence

Use this framework before treating any Leqvio side-effect claim, from this page or elsewhere online, as reliable.

Frequently asked questions